Abstract Reported herein are the synthesis and solidphase peptide incorporation of N-Fmoc-(2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid bis-pivaloyloxymethyl phosphoryl ester [Fmoc-Pmab(POM) 2 -OH, 2] as a phosphatase-stable phosphothreonine (pThr) mimetic bearing orthogonal protection suitable for the synthesis of Pmabcontaining peptides having bio-reversible protection of the phosphonic acid moiety. This represents the first report of a bio-reversibly protected pThr mimetic in a form suitable for facile solid-phase peptide synthesis.
tert-Butyl
. Synthetic phosphopeptides modeled on recognition sequences can serve as useful pharmacological tools for studying these PPIs (Eisele et al. 1999; Lu et al. 2012) . However, in cellular systems the bioavailability of phosphopeptides may be limited by the enzymatic lability of the phosphoryl ester bond toward phosphatases and poor membrane transport of the phosphoryl di-anionic species. While replacement of the phosphoryl ester oxygen by methylene or fluoromethylenes has addressed issues related to phosphatase hydrolysis for pTyr (Burke and Lee 2003) , pSer (Shapiro et al. 1993; Perich 1994; Nair et al. 1995; Panigrahi et al. 2009 ) and pThr (Berkowitz et al. 1996; Otaka et al. 2000; Liu et al. 2009 ), cell membrane transit can still be limited by the di-anionic charge of the resulting phosphonic acids. A general strategy for increasing the cell membrane permeability of phosphates and phosphonic acids is to mask their acidic functionality with neutral ''prodrug'' groups that can be removed enzymatically once the agent is within the cell. Although a variety of general prodrug strategies have been for phosphonic acids (Schultz 2003; Hecker and Erion 2008) , there are few reports detailing incorporation of these functionalities into protected amino acid derivatives that are amenable to solid-phase peptide synthesis. Recent examples of the latter include the application of 5 0 -nitrofuryl-2 0 -methyl N-(4 00 -chlorobutyl)phosphonamido ester prodrug strategy to the pTyr mimetic difluorophosphonomethylphenylalanine (F 2 Pmp) (Boutselis et al. 2007) and to the pSer mimetic, difluorophosphonoaminobutyric acid (Arrendale et al. 2012) . In these two cases, the prodrugprotected reagents were used to prepare dipeptides for examination in whole cell studies. The use of these reagents for the solid-phase synthesis of longer peptides is potentially limited by chemical instability of the phosphonamido group to repetitive cycles of piperidine treatment needed for Fmoc-based solid-phase protocols (Boutselis et al. 2007 ). In the broader sense, there is a paucity of reagents available for the solid-phase synthesis of polypeptides containing prodrug-protected pThr mimetics.
The pivaloyloxymethyl (POM) group is an esteraselabile moiety that has been widely applied to phosphoryl prodrug protection of nucleotides (Hecker and Erion 2008) and phosphate and phosphonic acid functionality in small molecules and peptide mimetics (Stankovic et al. 1997; Mandal et al. 2009 Mandal et al. , 2011 Zhao and Etzkorn 2007) . However, in spite of its usefulness in these latter contexts, there are no prior reports of polypeptides containing pThr, pSer or their phosphonic acid-based mimetics, bearing POM protection. Given the importance of pThr in a large number of biological processes (Elia and Yaffe 2005) , a reagent that would permit the solid-phase synthesis of polypeptides containing POM-protected pThr mimetics would be highly desirable.
We had previously reported the preparation of N-Fmoc- Fig. 1 ] as a hydrolytically-stable pThr mimetic bearing orthogonal protection suitable for the standard Fmoc-based synthesis of peptides containing Pmab. However this reagent yields peptides in which the Pmab residue has its phosphonic acid moiety in the free di-anionic form ). To date, there have been no reports of Pmab suitably derivatized for the solid-phase synthesis of polypeptides that maintained the phosphonic acid in a prodrug-protected form. In the current paper we describe the first preparation of FmocPmab having the phosphonic acid group masked as its POM bis-esters [Fmoc-Pmab(POM) 2 -OH, 2, Fig. 1 ] and demonstrate its use in the solid-phase synthesis of a peptide bearing full POM protection of the Pmab residue.
Materials and methods

General methods
All experiments involving moisture-sensitive compounds were conducted under anhydrous conditions. FmocSer(Trt)-OH, and Fmoc-His(Mtt)-OH were purchased from NovaChioChem. All solvents were purchased in anhydrous form (Aldrich) and used directly. Analytical TLCs were performed using Analtech precoated plates (Uniplate, silica gel GHLF, 250 nm) containing a fluorescence indicator. NMR spectra were recorded using a Varian Inova 400 MHz spectrometer. Coupling constants are reported in hertz, and peak shifts are reported in d (ppm) relative to TMS. Low-resolution mass spectra (ESI) were measured with an Agilent 260 1200 LC/MSD-SL system. High resolution mass spectra (HRMS) were obtained by positive ion, ESI analysis on a Thermo Scientific LTQ-XL Orbitrap mass spectrometer with HPLC sample introduction using a short narrow-bore C 18 reversed-phase column with CH 3 CN-H 2 O gradients. Reported m/z values are the average of eight or more scans over the chromatographic peak of interest. Liu et al. 2009 ) (0.26 g, 0.57 mmol) in THF-H 2 O (4:1; 5 mL) at 0°C was added a solution of LiOHÁH 2 O (48 mg, 1.14 mmol) and the mixture was stirred at room temperature until all starting material was consumed as indicated by TLC. The pH was adjusted to 2-3 by the addition of 1 N aqueous HCl and THF was removed by evaporation. The residue was extracted (EtOAc) and the combined organic phase was washed with brine, dried (MgSO 4 ), filtered and concentrated. To a solution of the crude residue in DMF (5.0 mL) were added sequentially, NaHCO 3 (95 mg, 1.14 mmol) and BnBr (0.10 mL, 0.85 mmol) at room temperature under argon and the mixture was stirred until the starting material was consumed as indicated by TLC. 156.4, 136.5, 135.4, 128.8, 128.7, 128.6, 128.3, 82.4 ((((2R,3S)-4-(Benzyloxy)-3-(((benzyloxy)carbonyl)amino)-2-methyl-4-oxobutyl)phosphoryl)bis(oxy))bis(methylene) Bis(2,2-dimethylpropanoate) (5) A solution of 4 (0.27 g, 0.5 mmol) in 10 % TFA (CH 2 Cl 2 ) was stirred at room temperature (1 h), then volatiles were removed under vacuum and the residue was taken up in DMF with pivaloyloxymethyl iodide (POMI) (Bandgar et al. 2011 ) (0.32 mL, 2.0 mmol) and DIPEA (0.35 mL, 2.0 mmol) and stirred at room temperature under argon (overnight). The mixture was diluted with H 2 O, extracted with EtOAc and the combined organic extracts were washed with H 2 O, and brine, dried (MgSO 4 ), filtered and concentrated. Purification by silica gel chromatography (EtOAc : hexanes from 1:4 to 1:1) afforded 5 as a white semi-solid (0.24 g, 74 % yield for two steps, Scheme 1 Use of reagent 2 for the solid-phase synthesis of peptide 6 Standard Fmoc-protected amino acids were purchased from Novabiochem. Peptides were synthesized on NovaSyn Ò TG Sieber resin (Novabiochem, cat. no. 01-64-0092) using Fmoc-based solid-phase protocols in N-methyl-2-pyrrolidone (NMP). 1-O-Benzotriazole-N,N,N 0 ,N 0 -tetramethyl-uroniumhexafluoro-phosphate (HBTU) (5.0 eq.), hydroxybenzotriazole (HOBT) (5.0 eq.) and N,N-diisopropylethylamine (DIPEA) (10.0 eq.) were used as coupling reagents. Reagent 2 was employed for introduction of the first residue. Following completion of peptide elongation and Fmoc-deprotection, amino terminal acetylation was achieved using 1-acetylimidazole. The finished resin (7, Scheme 2) was washed with DMF, MeOH, CH 2 Cl 2 and diethyl ether and then dried under vacuum (overnight). Peptide 6 was cleaved from the resin using 1 % TFA in CH 2 Cl 2 . The resin was removed by filtration and the filtrate was concentrated under vacuum, then precipitated with cold ether and the precipitate washed with cold ether. The resulting solid was dissolved in 50 % aqueous acetonitrile (5 mL) and purified by reverse phase preparative HPLC using a Phenomenex C 18 column (21 mm dia 9 250 mm, cat. no: 00G-4436-P0) with a linear gradient from 0 % aqueous acetonitrile (0.1 % TFA) to 100 % acetonitrile (0.1 % trifluoroacetic acid) over 30 min at a flow rate of 10.0 mL/min. Lyophilization gave peptide 6 as a white powder ( Following literature procedures (Srivastva and Farquhar 1984) , 0.05 M potassium phosphate buffer (pH 7.4) was Scheme 2 Synthesis of bis-POM-protected peptide 6 using reagent 2 placed in a centrifuge tube and a solution of peptide 6 in MeOH was added to achieve a concentration of 200 lM of 6 with MeOH being less than 1 %. To a 1 mL aliquot of the above solution was added pig liver esterase (57.6 units) and the reaction mixture was incubated at 37°C with gentle agitation. At various time points, aliquots of the reaction mixture (50 lL) were transferred to an Eppendorf tube containing MeCN (50 lL). Following filtration, the hydrolysis product was monitored by LC-MS. Data are shown in Fig. 2 .
Results and discussion
Preparation of reagent 2 began with Cbz-Pmab Bu t 2 À Á -OMe (3), which is an intermediate in our previously reported synthesis of 1 ). Benzyl trans-esterification of 3-4 was accomplished by initial LiOH-mediated hydrolysis of the methyl ester followed by reaction of the free acid with benzyl bromide (NaHCO 3 in DMF, 80 % yield for two steps, Scheme 1). Subsequent treatment of 4 with pivaloyloxymethyl iodide (POMI) (Bandgar et al. 2011 ) and diisopropylethyl amine (DIPEA) in DMF provided the corresponding bis-POM-protected intermediate (5). Hydrogenolytic removal of amino and carboxyl protecting groups and introduction of N-Fmoc-protection by treatment with 9-fluorenylmethyl succinimidyl carbonate (Fmoc-OSu) in aqueous THF with NaHCO 3 , gave the desired reagent 2 (55 % yield from 4) (Scheme 1).
In order to demonstrate the usefulness of 2 for the incorporation of Pmab(POM) 2 into peptides by solid-phase techniques, we chose the sequence, Ac-Pro-Leu-His-SerPmab-amide, which has previously shown to bind with good affinity to the polo-like kinase 1 (Plk1) polo box domain (PBD) (Yun et al. 2009; Liu et al. 2011 Liu et al. , 2012a . PBD-binding ligands may potentially serve as anti-cancer agents by blocking the spatial organization required for Plk1 to function in oncogenic processes (van de Weerdt et al. 2008) . The syntheses of Ac-Pro-Leu-His-SerPmab(POM) 2 -amide (6) was accomplished on NovaSyn TG Sieber resin using standard Fmoc protocols. Histidine and serine were employed in their 4-methoxytrityl (Mtt) and trityl (Trt) side chain-protected forms, respectively, to allow their cleavage under mildly acidic conditions (Scheme 2). Following synthesis completion, the resinbound Ac-Pro-Leu-His(Mtt)-Ser(Trt)-Pmab(POM) 2 -amide (7) was subjected to treatment with 1 % TFA, which resulted in removal of histidine and serine protecting groups and cleavage of the peptide from the resin with retention of Pmab-bis-POM functionality. Purification by HPLC provided Ac-Pro-Leu-His-Ser-Pmab(POM) 2 -amide (6) as a white solid (Scheme 2).
In order to examine the bio-reversibility of the Pmab POM protection of 6, we performed in vitro assays using porcine liver esterase (PLE) in phosphate buffer at pH 7.4 (Srivastva and Farquhar 1984) . We observed that the parent Pmab bis-POM-containing 6 was rapidly converted to the mono-POM-containing product (t 1/2 & 5 min) with further deprotection to the free Pmab-containing peptide occurring at a slower rate (20 % conversion over 8 h) (Fig. 2) . Reduction in the rate of enzymatic cleavage of a second POM group is known (Srivastva and Farquhar 1984 ).
Conclusions
Our current paper presents the synthesis of a reagent [Fmoc-Pmab(POM) 2 -OH (2)] that allows the facile synthesis of peptides containing the phosphatase-stable pThr mimetic, Pmab, bearing bio-reversible POM protection. This represents a rare example of a reagent that allows the solid-phase synthesis of polypeptides having a pThr mimetic in bio-reversible prodrug form. Reagent 2 should find utility in a variety of pharmacological applications.
